Literature DB >> 27567834

N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the REGARDS Cohort.

Mary Cushman1,2, Peter W Callas3, Leslie A McClure4, Frederick W Unverzagt5, Virginia J Howard6, Sarah R Gillett1, Evan L Thacker7, Virginia G Wadley8.   

Abstract

BACKGROUND: Improved understanding of the etiology of cognitive impairment is needed to develop effective preventive interventions. Higher amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker of cardiac dysfunction associated with risk of cardiovascular diseases and stroke in apparently healthy people.
OBJECTIVE: To study the association of NT-proBNP with risk of incident cognitive impairment.
METHODS: The Reasons for Geographic and Racial Differences in Stroke is a national cohort study of 30,239 black and white Americans age 45 and older at baseline, enrolled in 2003-7. Among participants without prebaseline stroke or cognitive impairment, baseline NT-proBNP was measured in 470 cases of incident cognitive impairment and 557 controls. Cases were participants scoring below the 6th percentile of demographically-adjusted means on at least 2 of 3 serially administered tests (word list learning, word list recall and semantic fluency) over 3.5 years follow-up.
RESULTS: Adjusting for age, gender, race, region of residence, education, and income, there was an increased odds ratio of incident cognitive impairment with increasing NT-proBNP; participants in the 4th versus 1st quartile (>127 versus ≤33 pg/ml) had a 1.69-fold increased odds (95% CI 1.11-2.58). Adjustment for cardiovascular risk factors and presence of an apolipoprotein E4 allele had no substantial impact on the odds ratio. Results did not differ by age, race, gender, or presence of an apolipoprotein E4 allele.
CONCLUSION: Higher NT-pro-BNP was associated with incident cognitive impairment in this prospective study, independent of atherogenic and Alzheimer's disease risk factors. Future work should clarify pathophysiologic connections of NT-proBNP and cognitive dysfunction.

Entities:  

Keywords:  Biomarkers; brain; cognition disorders; natriuretic peptide; prospective study; risk factors

Mesh:

Substances:

Year:  2016        PMID: 27567834     DOI: 10.3233/JAD-160328

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  15 in total

1.  Biomarkers as MEDiators of racial disparities in risk factors (BioMedioR): Rationale, study design, and statistical considerations.

Authors:  D Leann Long; Boyi Guo; Leslie A McClure; Byron C Jaeger; Stephanie E Tison; George Howard; Suzanne E Judd; Virginia J Howard; Timothy B Plante; Neil A Zakai; Insu Koh; Katharine L Cheung; Mary Cushman
Journal:  Ann Epidemiol       Date:  2021-11-03       Impact factor: 3.797

2.  N-Terminal pro-B-type natriuretic peptide and stroke risk across a spectrum of cerebrovascular disease: The REasons for Geographic and Racial Differences in Stroke cohort.

Authors:  Kara K Landry; Suzanne E Judd; Dawn O Kleindorfer; George Howard; Virginia J Howard; Neil A Zakai; Mary Cushman
Journal:  Res Pract Thromb Haemost       Date:  2020-06-14

3.  Soluble ST2 and risk of cognitive impairment after acute ischemic stroke: a prospective observational study.

Authors:  Yinwei Zhu; Chongquan Fang; Qi Zhang; Yaling Lu; Rui Zhang; Aili Wang; Xiaoqing Bu; Jintao Zhang; Zhong Ju; Yonghong Zhang; Tan Xu; Chongke Zhong
Journal:  BMC Geriatr       Date:  2021-05-24       Impact factor: 3.921

Review 4.  Vascular-brain Injury Progression after Stroke (VIPS) study: concept for understanding racial and geographic determinants of cognitive decline after stroke.

Authors:  Fred Stephen Sarfo; Rufus Akinyemi; George Howard; Virginia J Howard; Kolawole Wahab; Mary Cushman; Deborah A Levine; Adesola Ogunniyi; Fred Unverzagt; Mayowa Owolabi; Bruce Ovbiagele
Journal:  J Neurol Sci       Date:  2020-02-19       Impact factor: 4.553

5.  Subclinical Atherosclerosis, Cardiac and Kidney Function, Heart Failure, and Dementia in the Very Elderly.

Authors:  Lewis H Kuller; Oscar L Lopez; John S Gottdiener; Dalane W Kitzman; James T Becker; Yuefang Chang; Anne B Newman
Journal:  J Am Heart Assoc       Date:  2017-07-22       Impact factor: 5.501

6.  N-terminal pro-B-type natriuretic peptide and microsize myocardial infarction risk in the reasons for geographic and racial differences in stroke study.

Authors:  Madeline R Sterling; Raegan W Durant; Joanna Bryan; Emily B Levitan; Todd M Brown; Yulia Khodneva; Stephen P Glasser; Joshua S Richman; George Howard; Mary Cushman; Monika M Safford
Journal:  BMC Cardiovasc Disord       Date:  2018-04-16       Impact factor: 2.298

7.  Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites.

Authors:  Anand Venkatraman; Peter Callas; Leslie A McClure; Fred Unverzagt; Garima Arora; Virginia Howard; Virginia G Wadley; Mary Cushman; Pankaj Arora
Journal:  Alzheimers Dement (N Y)       Date:  2018-04-26

8.  N-Terminal pro-Brain Natriuretic Peptide and Associations With Brain Magnetic Resonance Imaging (MRI) Features in Middle Age: The CARDIA Brain MRI Study.

Authors:  Ian T Ferguson; Martine Elbejjani; Behnam Sabayan; David R Jacobs; Osorio Meirelles; Otto A Sanchez; Russell Tracy; Nick Bryan; Lenore J Launer
Journal:  Front Neurol       Date:  2018-05-07       Impact factor: 4.003

9.  Preoperative N-terminal pro-B-type natriuretic peptide concertation and prognosis of brain tumor patients: a 5-year follow up study.

Authors:  Adomas Bunevicius; Vytenis Deltuva; Edward R Laws; Giorgio Iervasi; Arimantas Tamsauskas; Robertas Bunevicius
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

10.  Clinical and Biological Correlates of Preoperative Cognitive Functioning of Glioma and Meningioma Patients.

Authors:  Aiste Pranckeviciene; Vytenis P Deltuva; Arimantas Tamasauskas; Jurate Zegliene; Adomas Bunevicius
Journal:  Biomed Res Int       Date:  2020-05-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.